May 09, 2016
Cadwalader is representing The Medicines Company (NASDAQ: MDCO), a provider of solutions in serious infectious disease care, acute cardiovascular care and surgery and perioperative care, in its agreement to divest three of its marketed cardiovascular products – Cleviprex® (clevidipine) injectable emulsion, Kengreal® (cangrelor) and rights to Argatroban® for Injection – and related assets to Chiesi Farmaceutici S.p.A., for up to $792 million, consisting of $260 million in cash payable at closing, up to $480 million in sales-based milestone payments, the assumption by Chiesi of up to $50 million in milestone payment obligations and approximately $2 million for product inventory.
The Cadwalader team is led by Corporate partners Greg Patti and Andy Alin and includes Corporate associates Gaël Hagan, Alexandra Cotter, Tyler Carson, Timothy Polmateer, and Mattan Erder, and visiting law clerk Kenji Horiuchi in New York; Antitrust partner Rick Rule and associate Christian Lorenz in Washington, D.C.; Tax partner Linda Swartz and special counsel Edward Wei in New York; Intellectual Property partner Dorothy Auth and special counsel Howard Wizenfeld in New York; and Employee Benefits and Executive Compensation special counsel Gillian Moldowan in New York.
The Medicines Company’s purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on the leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: serious infectious disease care, acute cardiovascular care and surgery and perioperative care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers in Parsippany, NJ, USA and Zurich, Switzerland. www.themedicinescompany.com.
Richard Brand, Brian McGovern
Joseph Moreno, Anne Tompkins
Robert Cannon will discuss the U.K.’s new insurance-linked securities framework.